A Breathalyzer for Disease
Our Mission: To save 100,000 lives and $1.5B in healthcare costs.
Our Vision: The global leader in Breath Biopsy® for early detection and precision medicine.
About Owlstone Medical
Owlstone Medical is at the forefront of breath biomarker research and development, leading to non-invasive diagnostic tests that can improve early disease detection and precision medicine across different fields including cancer, respiratory, gastrointestinal, the microbiome and liver disease. We offer Breath Biopsy research products and services that enable the comprehensive and reliable analysis of volatile organic compounds from a range of sample types from in vitro cell culture to human breath.
Our Latest Updates
Owlstone Announces Investment from Bill and Melinda Gates Foundation
Owlstone Medical secures $6.5 million to support the development of breath-based diagnostics for infectious diseases.
Owlstone Medical Enters into a Research Collaboration Agreement with the FDA
The collaboration will develop analytical methods to improve the identification of specific chemicals in complex gaseous mixtures.
Owlstone Publishes New VOC Atlas Paper
“High-quality identification of volatile organic compounds (VOCs) originating from breath”, published in Metabolomics. Building the foundations of our soon-to-release Breath Biopsy VOC Atlas®.
Breath Biopsy Conference 2024
Join us for our two day online conference where the key areas of breath research will be explored through talks, poster sessions and discussions.